ITGAX and Guillain-Barre syndrome: Antigen-presenting cell activity of myeloid dendritic cells may contribute to the maintenance of T-cell activation in GBS, with increased numbers of CD11c(+) myeloid DCs versus CD123(+) plasma cell-like DCs in patients with GBS before treatment with high-dose IVIG (31).